<DOC>
	<DOC>NCT00614575</DOC>
	<brief_summary>The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy. i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation</brief_summary>
	<brief_title>Survey on PD Patients With Depressive Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criteria: **PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance. Exclusion criteria: PD patients with the past history of suicidal attempt, suicidal ideation or tendency PD patients with suicidal ideation PD patients with the past history of suicidal tendency</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>